Context Therapeutics Inc. reported its financial results for the first quarter ended March 31, 2025, on May 7, 2025. The company announced cash and cash equivalents of $89.4 million as of March 31, 2025, and expects this to fund operations into 2027.
The company has two product candidates, CTIM-76 and CT-95, now in Phase 1 clinical trials. Research and development expenses increased by approximately $1.50 million, or 76%, to $3.46 million for the three months ended March 31, 2025, compared to the same period in 2024. General and administrative expenses also saw a modest increase of approximately $0.20 million, reaching $2.07 million.
Context expects to report initial clinical data for CTIM-76 in the first half of 2026 and for CT-95 by mid-2026. The company also plans to file an IND for CT-202 in mid-2026, continuing to advance its portfolio of T cell-engaging therapies for solid tumors.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.